X0306 4 2022-09-27 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001913961 Habibizad Nazila C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-09-27 4 M 0 23597 12.95 A 35465 D Common Stock 2022-09-27 4 M 0 3005 29.75 A 38470 D Common Stock 2022-09-27 4 M 0 2043 59.60 A 40513 D Common Stock 2022-09-27 4 M 0 1027 48.44 A 41540 D Common Stock 2022-09-27 4 M 0 83 46.99 A 41623 D Stock Option (Right to Buy) 12.95 2022-09-27 4 M 0 23597 0.00 D 2026-02-08 Common Stock 23597 0 D Stock Option (Right to Buy) 29.75 2022-09-27 4 M 0 3005 0.00 D 2027-02-28 Common Stock 3005 5995 D Stock Option (Right to Buy) 59.60 2022-09-27 4 M 0 2043 0.00 D 2028-01-31 Common Stock 2043 5957 D Stock Option (Right to Buy) 48.44 2022-09-27 4 M 0 1027 0.00 D 2029-01-31 Common Stock 1027 4448 D Stock Option (Right to Buy) 46.99 2022-09-27 4 M 0 83 0.00 D 2029-09-30 Common Stock 83 7917 D The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 30,000 shares on January 11, 2017 and in 12 equal quarterly installments thereafter through January 11, 2020. The shares of Common Stock underlying the stock option vested in 16 quarterly installments from March 1, 2017 through March 1, 2021. The shares of Common Stock underlying the stock option vested in 16 quarterly installments from February 1, 2018 through February 1, 2022. The shares of Common Stock underlying the stock option vest in 16 quarterly installments from February 1, 2019 through February 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vest in 16 quarterly installments from October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Executive Vice President, Operations /s/ Miguel Carrillo, Attorney-in-Fact 2022-09-29